BACKGROUND AND OBJECTIVE: Sentinel lymph node excision (SLNE) and positron emission tomography (PET) were evaluated in the staging of 51 Stage I and II melanoma patients (staged according to the guidelines of the German Dermatological Society). PATIENTS/METHODS AND RESULTS: Tumor thickness ranged from 1.0 mm to 6.0 mm (median: 1.5 mm; mean: 2.07 mm). At least one sentinel lymph node (SLN) was excised in all patients; 80 SLN were excised from 69 lymphatic drainage areas. Positive SLN were detected in 6 patients (11.8%). Additional positive lymph nodes were not detected in any of these patients in the following complete lymph node dissection of the affected lymph node basin. Preoperative PET was performed in 40 patients and did not detect any of the micrometastases that were subsequently found by SLNE. During the follow up of 7-40 months (mean 21.9 months) 3 patients experienced tumor progression; 2 of 3 had a positive SLN. CONCLUSIONS: According to the current literature SLNE is recommended in primary tumors greater than 1 mm thickness. PET cannot be expected to give additional information in the staging of stage I-II patients.
BACKGROUND AND OBJECTIVE: Sentinel lymph node excision (SLNE) and positron emission tomography (PET) were evaluated in the staging of 51 Stage I and II melanoma patients (staged according to the guidelines of the German Dermatological Society). PATIENTS/METHODS AND RESULTS: Tumor thickness ranged from 1.0 mm to 6.0 mm (median: 1.5 mm; mean: 2.07 mm). At least one sentinel lymph node (SLN) was excised in all patients; 80 SLN were excised from 69 lymphatic drainage areas. Positive SLN were detected in 6 patients (11.8%). Additional positive lymph nodes were not detected in any of these patients in the following complete lymph node dissection of the affected lymph node basin. Preoperative PET was performed in 40 patients and did not detect any of the micrometastases that were subsequently found by SLNE. During the follow up of 7-40 months (mean 21.9 months) 3 patients experienced tumor progression; 2 of 3 had a positive SLN. CONCLUSIONS: According to the current literature SLNE is recommended in primary tumors greater than 1 mm thickness. PET cannot be expected to give additional information in the staging of stage I-II patients.
Authors: K M Acland; C Healy; E Calonje; M O'Doherty; T Nunan; C Page; E Higgins; R Russell-Jones Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: M A Gadd; A B Cosimi; J Yu; L M Duncan; L Yu; T J Flotte; W W Souba; M J Ott; L S Wong; A J Sober; M C Mihm; F G Haluska; K K Tanabe Journal: Arch Surg Date: 1999-04
Authors: D S Tyler; M Onaitis; A Kherani; A Hata; E Nicholson; M Keogan; S Fisher; E Coleman; H F Seigler Journal: Cancer Date: 2000-09-01 Impact factor: 6.860
Authors: J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: Felix M Mottaghy; Cord Sunderkötter; Roland Schubert; Petra Wohlfart; Norbert M Blumstein; Bernd Neumaier; Gerhard Glatting; Cueneyt Ozdemir; Andreas K Buck; Karin Scharffetter-Kochanek; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2007-02-13 Impact factor: 9.236
Authors: Vinod B Shidham; Richard Komorowski; Marcelle Neuberg; Alonzo Walker; Bruce H Campbell; Chung-Che Chang; William W Dzwierzynski Journal: Diagn Pathol Date: 2006-09-25 Impact factor: 2.644